Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Ironwood Pharmaceuticals (IRWD) Divestments (2018 - 2019)

Ironwood Pharmaceuticals' Divestments history spans 3 years, with the latest figure at -$4.2 million for Q1 2019.

On a quarterly basis, Divestments changed N/A to -$4.2 million in Q1 2019 year-over-year; TTM through Dec 2019 was -$4.2 million, a 241.52% decrease, with the full-year FY2019 number at -$4.2 million, up 48.94% from a year prior.
Divestments hit -$4.2 million in Q1 2019 for Ironwood Pharmaceuticals, down from -$3.0 million in the prior quarter.
Over the last five years, Divestments for IRWD hit a ceiling of -$3.0 million in Q4 2018 and a floor of -$4.2 million in Q1 2019.